The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

So how the treatment changed depending on grade is really, if we look at the IDH mutated patient, right? So, there is grade 2, 3 and 4 and now for grade 2 patients, really the treatment is ...